Novel oral anticoagulants in intracardiac thrombosis resolution: a case series

Vitamin K antagonists (VKAs) have been regarded as the therapy of choice for intracardiac thrombosis for decades based mostly on observational data. The advent of direct oral anticoagulants (DOACs) has displaced VKAs as the first-line therapy for multiple thrombotic disorders but not for intracardia...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal : case reports Vol. 4; no. 5; pp. 1 - 6
Main Authors Al-Sadawi, Mohammed, Francois, Jonathan, Rodriguez Ortega, Romy, Capric, Violeta, Budzikowski, Adam S
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.10.2020
Subjects
Case Series
Case series
DOAC
Intracardiac thrombosis
Oral anticoagulants
Online AccessGet full text

Cover

More Information
Summary:Vitamin K antagonists (VKAs) have been regarded as the therapy of choice for intracardiac thrombosis for decades based mostly on observational data. The advent of direct oral anticoagulants (DOACs) has displaced VKAs as the first-line therapy for multiple thrombotic disorders but not for intracardiac thrombosis. Although limited, there is growing evidence that DOACs are effective for intracardiac thrombosis and some data suggest that thrombus resolution might be superior to that with warfarin. Here, we present a series of six patients with left atrial appendage thrombi were treated with a venous thromboembolic dose of DOACs with resolution within 2-6 months with no reported complications. This case series adds to the accumulating evidence supporting the efficacy of DOACs in the treatment of intracardiac thrombi.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2514-2119
2514-2119
DOI:10.1093/ehjcr/ytaa181